Will OPKO Health stock trade lower or higher?
The rapid run-up in its shares prompted Hindenburg Research, a short-seller that's been bearish on OPKO Health since 2018, to reassert its belief that it will trade significantly lower, not higher. Image source: Getty Images.
What's going on with OPKO Health's BioReference labs?
OPKO Health's BioReference Labs is one of the largest patient testing laboratories in the United States. On March 5, it announced plans to roll out a test for the COVID-19 coronavirus, which sent OPKO's shares soaring .
Is OPKO Health burning through cash?
There's no question that OPKO Health is burning through cash. In 2019, the healthcare company reported a $315 million net loss on revenue of $224 million. As a result, OPKO's cash balance slipped to $85.5 million from $96.5 million exiting 2018, despite raising $81.3 million via an underwritten public stock offering in Q4.
How can I get the latest news and ratings for OPK?
Sign up to receive the latest news and ratings for OPK and its competitors with MarketBeat's FREE daily newsletter. View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Does opko stock pay a dividend?
OPKO Health, Inc. has not declared or paid cash dividends. The company has retained earnings for the operation and expansion of its business and does not anticipate paying any cash dividends in the foreseeable future.
What is the forecast for OPK stock?
Stock Price Forecast The 4 analysts offering 12-month price forecasts for OPKO Health Inc have a median target of 6.25, with a high estimate of 8.50 and a low estimate of 5.00. The median estimate represents a +159.34% increase from the last price of 2.41.
Is OPK a short squeeze?
Find powerful squeezes happening now!...OPK (NYSE)Short Squeeze Ranking™viewShort Interest (Shares Short)44,930,000Short Interest Ratio (Days To Cover)9.9Short Percent of Float10.90 %4 more rows
Is OPK stock a good buy?
Is Opko Health Stock a good buy in 2022, according to Wall Street analysts? The consensus among 2 Wall Street analysts covering (NASDAQ: OPK) stock is to Buy OPK stock.
Will OPK go up?
Based on our forecasts, a long-term increase is expected, the "OPK" stock price prognosis for 2027-05-26 is 6.358 USD. With a 5-year investment, the revenue is expected to be around +115.53%. Your current $100 investment may be up to $215.53 in 2027.
Is Xela stock good?
The financial health and growth prospects of XELA, demonstrate its potential to perform inline with the market. It currently has a Growth Score of C. Recent price changes and earnings estimate revisions indicate this would be a good stock for momentum investors with a Momentum Score of A.
Is opko shorted?
OPKO Health (OPK -7.54%) is a highly shorted stock -- 24% of its float is sold short.
Is Cprx good investment?
The financial health and growth prospects of CPRX, demonstrate its potential to outperform the market. It currently has a Growth Score of C. Recent price changes and earnings estimate revisions indicate this would be a good stock for momentum investors with a Momentum Score of A.
What does opko Health do?
A Diverse Healthcare Company Focused on Improving Patient Lives. At OPKO Health, we seek to serve unmet patient needs through our first in class products, comprehensive diagnostics laboratories, robust research and development pipeline, and unique pharmaceutical business solutions.
How much is OPKO Health earnings per share 2021?
What is Zacks research?
OPKO Health, Inc. reported first-quarter 2021 adjusted earnings per share of 5 cents per share, which met the Zacks Consensus Estimate. Notably, the company had reported a loss of 9 cents in the prior-year quarter.
OPKO Health (OPK) Gains As Market Dips: What You Should Know
Zacks. Zacks is the leading investment research firm focusing on stock research, analysis and recommendations. In 1978, our founder discovered the power of earnings estimate revisions to enable profitable investment decisions. Today, that discovery is still the heart of the Zacks Rank.
7 Insider Stocks to Buy as Execs Snap Them Up
In the latest trading session, OPKO Health (OPK) closed at $3.15, marking a +0.32% move from the previous day.
Pfizer (PFE) Gets EU Nod for Somatrogon & Pneumococcal Jab
With so much information proliferating the internet about equity market opportunities, it’s hard to know whom to trust. That’s especially the case when you consider insider stocks or transactions that corporate insiders — executives, high-level employees and major stakeholders — execute on the companies with which they are associated.
OPKO's (OPK) NGENLA to Offer GHD Treatment in European Union
Pfizer (PFE) gets approval for pediatric growth hormone deficiency drug, Ngenla (somatrogon) and 20-valent pneumococcal conjugate vaccine, Apexxnar, in Europe.
OPKO Health (OPK) to Post Q4 Earnings: What's in the Cards?
OPKO's (OPK) marketing authorization for NGENLA in the European Union stands to benefit children and adolescents affected by growth hormone deficiency.
Analysts Estimate OPKO Health (OPK) to Report a Decline in Earnings: What to Look Out for
OPKO Health's (OPK) fourth-quarter results are likely to reflect strength in Rayaldee.
Quotient (QTNT) Reports Q3 Loss, Tops Revenue Estimates
OPKO Health (OPK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
OPKO Health Q2 Earnings and Revenues Beat Estimates
Quotient (QTNT) delivered earnings and revenue surprises of -76% and 10.57%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Segmental Revenues in Q2
OPKO Health, Inc. reported second-quarter 2020 adjusted earnings per share of 5 cents per share against the Zacks Consensus Estimate of a loss of 7 cents.
What happened
Revenues from Services amounted to $251 million in the reported quarter, up 41% year over year. The upside can be attributed to increased COVID-19 testing volumes.
So what
A rough day for the broad market is a downright terrible one for Opko Health (NASDAQ: OPK). Shares of the drug and diagnostics outfit were down by 23% as of 1:22 p.m.
Now what
The drug in question, somatrogon, aims to treat growth hormone deficiency in children. Pfizer and Opko have been working together on the treatment since 2014. Although approved in some overseas markets, the FDA has issued what is called a Complete Response Letter (CRL) regarding the drug's potential approval within the all-important U.S. market.
The Motley Fool
Somatrogon was a more important prospect for Opko Health than for Pfizer, whose stock is only lower by 4.8% today (and much of that weakness can be attributed to the marketwide sell-off). Indeed, Pfizer's portfolio and pipeline remain large enough that today's pullback could be a good entry opportunity for true long-term investors.
What is the strongest trending metric for OPK?
Founded in 1993 in Alexandria, VA., by brothers David and Tom Gardner, The Motley Fool is a multimedia financial-services company dedicated to building the world's greatest investment community.
Where is Opko Health located?
OPK's strongest trending metric is Stability; it's been moving up over the last 31 weeks. OPK's current lowest rank is in the Sentiment metric (where it is better than 11.16% of US stocks).
Is Opko Health a bearish company?
The company was founded in 2005 and is based in Miami, Florida.
Is Opko Health burning through cash?
The rapid run-up in its shares prompted Hindenburg Research, a short-seller that's been bearish on OPKO Health since 2018, to reassert its belief that it will trade significantly lower, not higher.
What happened
There's no question that OPKO Health is burning through cash. In 2019, the healthcare company reported a $315 million net loss on revenue of $224 million. As a result, OPKO's cash balance slipped to $85.5 million from $96.5 million exiting 2018, despite raising $81.3 million via an underwritten public stock offering in Q4.
So what
After reporting a year-over-year decline in revenue that was worse than industry watchers expected, OPKO Health ( OPK -3.17% ) saw its shares fall 16.7% on Thursday.
NASDAQ: OPK
Although the healthcare company is benefiting from significant demand for COVID-19 tests, rising demand in the final weeks of the first quarter wasn't enough to offset declining demand for lab services caused by widespread shelter-in-place orders that reduced visits to primary- and specialty-care doctors.
Now what
The company's net loss per share was $0.09 on a GAAP basis, which was in line with analyst forecasts. Its $59.1 million net loss was an improvement from an $80.8 million net loss last year.
Premium Investing Services
OPKO Health began providing testing for the SARS-CoV-2 coronavirus in various states, including New York, on March 13. Initially, volume was limited because of testing constraints, but volume has expanded significantly over the past month.
